The market didn't appreciate Amgen 's ( AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more ...

Data from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.

Few companies garner as much reliable attention as Novo Nordisk ( NVO) does these days. With a bull market coinciding with a ...

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

This article summarizes current health news, covering topics like potential bone loss from thyroid medication, dementia risks from wildfire smoke, and updates on pharmaceutical pricing policies. It ...

Amgen's MariTide shows promising weight loss results in Phase II for type 2 diabetes. Find out why AMGN stock remains as a strong buy for long-term investors.

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

A new experimental weight loss drug from Amgen — the first in a growing group of drugs aimed at once-a-month injections instead of once a week — helped patients lose up to 20% of their weight in one ...

Mizuho Securities analyst Salim Syed has maintained their neutral stance on AMGN stock, giving a Hold rating yesterday.Don't Miss our Black ...

Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

Study subjects taking the company’s MariTide lost about 20% of their weight in the 52-week trial.

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.